Innocan Pharma Corporation

Recent News

  • Innocan Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 16, 2020) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan's CBD loaded liposome platform technology ("LPT") in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and...

    2020-11-16 3:00 AM ET
  • Innocan Enters Into Distribution Agreement to Sell its CBD Derma Cosmetic Products in Germany

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 11, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a distribution agreement dated 4, 2020 (the "Agreement") with iAmHealth Distribution UG ("iAmHealth"), a CBD products provider in Germany to sell the Company's SHIR Beauty and Relief & Go product lines in Germany. Under the terms of the Agreement, iAmHealth will...

    2020-11-11 4:00 PM ET
  • Innocan Pharma's Relief & Go CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 27, 2020) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report ("CPSR") for product marketing in the European Union.

    2020-10-27 4:00 PM ET
  • Innocan Pharma Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 23, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the recent publication of two scientific articles supporting Innocan's approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients" published in the Journal of Stem Cell Research & Therapy on...

    2020-10-23 2:00 AM ET
  • Innocan Pharma's Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief &Go OTC Pain Relief Spray

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 19, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today a Clinical Study, conducted by Dr. Josef Geldwert and the Center for Podiatric Care & Sports Medicine in New York. The study indicates that more than 90 % of participants experienced reduction in pain after using Innocan's Relief & Go OTC Pain Relief Spray. The clinical study was conducted on 18 participants: 10...

    2020-10-19 3:00 PM ET
  • Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 9, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol ("CBD") into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan's licensed CBD loaded liposome platform technology ("LPT") for injectable CBD. The study which...

    2020-10-09 3:00 PM ET
  • Innocan Pharma to Provide a Corporate Update via Livestream Video

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 8, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST. The update will include a corporate presentation by Innocan's CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by...

    2020-10-08 3:00 PM ET
  • Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 15, 2020) -   Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol ("CBD") (the "Serum") on skin hydration.

    2020-09-15 3:00 PM ET